Mysterious Stomach Pain in 13-Year-Old Solved by Apollo Doctor After CT Scan and Blood Work Yielded No Answers |
A 13-year-old boy from Maharashtra suffered from recurring episodes of severe abdominal pain and vomiting for over three years, despite numerous doctor visits and normal test results. His symptoms, which occurred every 6-8 weeks, included throbbing headaches, severe abdominal pain, and vomiting, leaving him incapacitated for 1-2 days. The boy’s case was eventually diagnosed as abdominal migraine, a condition characterized by chronic stomach pain, nausea, and vomiting, often triggered by stress, poor sleep, and exposure to bright light.
Abdominal migraine is a difficult-to-diagnose condition that affects 1-4% of school-going children, with girls being more prone to it than boys. The cause of abdominal migraine remains unknown, and there is no specific blood test or scan to diagnose it. Dr. Sudhir Kumar, a neurologist at Apollo Hospitals, highlighted the significance of abdominal migraine and the need for awareness among parents and healthcare professionals.
The boy’s diagnosis was made by Dr. Kumar after a thorough examination of his symptoms, family history, and episodic patterns. The treatment involved medications to target migraine symptoms, a proper sleep routine, stress management, and a balanced diet. Dr. Kumar also advised the boy’s parents to maintain a symptoms diary to track his episodes and triggers.
After treatment, the boy experienced remarkable growth and improvement, with his attacks stopping, and he was able to return to school and resume his favorite activity, playing cricket. Dr. Kumar advises parents and guardians to seek medical advice if their child experiences recurrent abdominal pain with persistent vomiting, even if scans are normal. He also emphasizes the importance of proper management of abdominal migraine, including medications, lifestyle changes, and stress management.
Dr. Kumar’s advice for parents and guardians includes:
* Seeking medical advice if the child experiences recurrent abdominal pain with persistent vomiting
* Not assuming that normal scans imply no underlying condition
* Maintaining a symptoms diary to track episodes and triggers
* Implementing lifestyle changes such as proper sleep routine, stress management, and a balanced diet
* Avoiding known dietary triggers
Overall, the case highlights the importance of awareness and proper diagnosis of abdominal migraine in children, and the need for parents and healthcare professionals to work together to manage the condition and improve the child’s quality of life.
Aurobindo Pharma’s Rajasthan-based facility receives 9 observations from the US FDA.
Aurobindo Pharma, a leading pharmaceutical company, has received nine observations from the US Food and Drug Administration (USFDA) for its facility in Rajasthan, India. The USFDA had conducted an inspection of the facility from January 27 to February 5, 2020. The observations were issued in the form of a Form 483, which is a document that outlines the concerns and deviations from regulatory requirements observed during an inspection.
The nine observations are related to various aspects of the facility’s operations, including quality control, documentation, and manufacturing processes. The USFDA has identified issues with the facility’s systems for ensuring the quality of its products, including the handling of complaints, deviations, and out-of-specification results. The agency has also raised concerns about the facility’s documentation practices, including the accuracy and completeness of records.
Aurobindo Pharma has stated that it is taking the observations seriously and is working to address the concerns raised by the USFDA. The company has said that it will provide a detailed response to the USFDA, including a corrective action plan to rectify the issues identified during the inspection. The company is confident that it can resolve the issues and is committed to ensuring the quality and compliance of its products.
The USFDA’s observations are not uncommon, and many pharmaceutical companies receive similar observations during inspections. However, the observations can have significant implications for the company’s business, as they can impact the company’s ability to export products to the US market. Aurobindo Pharma is a significant player in the US generic pharmaceutical market, and any disruption to its exports could have a significant impact on its revenue.
Aurobindo Pharma has a history of receiving USFDA observations, and the company has previously taken steps to address similar issues. In 2019, the company received 14 observations from the USFDA for its facility in Andhra Pradesh, India. The company has since implemented corrective actions and has received approval from the USFDA to resume exports from the facility.
Overall, Aurobindo Pharma’s Rajasthan facility has received nine USFDA observations, which the company is working to address. While the observations are a concern, the company is confident that it can resolve the issues and maintain its compliance with US regulatory requirements. The company’s ability to address the observations and maintain its quality and compliance standards will be critical to its success in the US market.
Mankind Pharma slapped with INR 83 lakh GST penalty, to file appeal.
Mankind Pharma, a leading Indian pharmaceutical company, has been slapped with a Goods and Services Tax (GST) penalty of INR 83 lakh (approximately USD 110,000) by the GST authorities. The penalty was imposed due to alleged irregularities in the company’s GST returns and invoices.
According to reports, the GST authorities conducted an investigation into Mankind Pharma’s financial records and discovered discrepancies in the company’s GST returns and invoices. The authorities alleged that the company had not paid the correct amount of GST on its sales and had also claimed incorrect input tax credits.
As a result, the GST authorities imposed a penalty of INR 83 lakh on the company. Mankind Pharma has stated that it plans to appeal against the penalty, claiming that the allegations are baseless and that the company has complied with all GST regulations.
The company’s management has expressed surprise at the penalty, stating that it has always followed the law and has a robust system in place to ensure compliance with GST regulations. Mankind Pharma has a strong track record of compliance with regulatory requirements and has always maintained transparency in its financial dealings.
The penalty imposed on Mankind Pharma is a significant development in the Indian pharmaceutical industry, which has been facing several challenges in recent times. The industry has been grappling with issues such as price controls, regulatory hurdles, and intense competition, which have impacted the profitability of several companies.
The GST penalty imposed on Mankind Pharma is likely to have a negative impact on the company’s financial performance in the short term. However, the company’s management is confident that it will be able to appeal against the penalty and get it revoked. Mankind Pharma has a strong financial position and a diversified product portfolio, which will help it to weather the challenges posed by the GST penalty.
In conclusion, Mankind Pharma’s GST penalty is a significant development in the Indian pharmaceutical industry. The company plans to appeal against the penalty, and its management is confident that it will be able to get it revoked. The outcome of the appeal will be closely watched by the industry, as it will have implications for the compliance requirements of pharmaceutical companies in India. With its strong financial position and diversified product portfolio, Mankind Pharma is well-equipped to handle the challenges posed by the GST penalty.
Natco Pharma’s Q2 net profit plunges 23.44% to Rs 517.9 crore
Natco Pharma, a leading Indian pharmaceutical company, has reported a decline in its net profit for the second quarter (Q2) of the current financial year. The company’s net profit stood at Rs 517.9 crore, which represents a decline of 23.44% compared to the same period last year.
The decline in net profit can be attributed to various factors, including a decrease in revenue and an increase in expenses. The company’s revenue from operations declined by 14.5% to Rs 1,217.5 crore during the quarter, compared to Rs 1,422.5 crore in the same period last year.
The decline in revenue was primarily due to a decrease in sales of certain key products, including those related to the treatment of cancer and hepatitis. Additionally, the company’s exports to the US market were also affected due to increased competition and regulatory issues.
Despite the decline in revenue, the company’s operating expenses increased by 10.5% to Rs 632.1 crore during the quarter, primarily due to higher research and development (R&D) expenses and selling and distribution expenses.
The company’s R&D expenses increased by 25.5% to Rs 143.1 crore during the quarter, as it continued to invest in new product development and clinical trials. The company’s selling and distribution expenses also increased by 12.1% to Rs 245.5 crore, primarily due to higher marketing and promotional expenses.
The decline in net profit has been a concern for the company, and it is taking steps to improve its performance. The company is focusing on launching new products, expanding its presence in emerging markets, and improving its operational efficiency.
In a statement, the company’s management said that it is confident of returning to growth in the coming quarters, driven by the launch of new products and an improvement in sales of its existing products. The company is also focusing on reducing its costs and improving its profitability.
Overall, while the decline in net profit is a concern, the company’s management is optimistic about its future prospects and is taking steps to improve its performance. The company’s focus on new product development, expansion into emerging markets, and operational efficiency is expected to drive growth in the coming quarters.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.